INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
Public company

RPRXRoyalty Pharma plc

CIK 0001802768

EDGAR filingsOpen in network
Disclosed transactions56
Buys / sells0 / 39
Max Insider Score33
Connections6with evidence

RPRX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
BL
Bassler Bonnie LDirector
RPRXRoyalty Pharma plc
Grant or award
A$37K
642 sh
Sep 30, 2026Sep 30, 2026
traded Sep 30, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Bassler Bonnie LDirector · Jun 30, 2026
  • ← Insider ofevidence
    Urist MarshallEVP, Research & Investments · Nov 7, 2025
  • ← Insider ofevidence
    Hite ChristopherEVP & Vice Chairman · Nov 7, 2025
18
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL
$239K
4,126 sh
Sep 28, 2026
Sep 30, 2026
traded Sep 28, 2026
+2d
SEC FORM 4

Evidence

9
HC
Hite ChristopherEVP & Chairman, Partnering
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$231K
3,927 sh
Sep 22, 2026Sep 24, 2026
traded Sep 22, 2026
+2dSEC FORM 4

Evidence

23
HC
Hite ChristopherEVP & Chairman, Partnering
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$5.62M
96.1K sh
Sep 22, 2026Sep 24, 2026
traded Sep 22, 2026
+2dSEC FORM 4

Evidence

23
HC
Hite ChristopherEVP & Chairman, Partnering
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$6.00M
100.0K sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

10
HC
Hite ChristopherEVP & Chairman, Partnering
RPRXRoyalty Pharma plc
Gift · 10b5-1 plan
G—
16.8K sh
Aug 19, 2026Aug 19, 2026
traded Aug 19, 2026
+0dSEC FORM 4

Evidence

21
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$541K
9,230 sh
Aug 13, 2026Aug 17, 2026
traded Aug 13, 2026
+4dSEC FORM 4

Evidence

18
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$105K
1,772 sh
Aug 13, 2026Aug 17, 2026
traded Aug 13, 2026
+4dSEC FORM 4

Evidence

5
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Gift
G—
3,000 sh
Aug 7, 2026Aug 7, 2026
traded Aug 7, 2026
+0dSEC FORM 4

Evidence

5
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Gift
G—
18.5K sh
Aug 7, 2026Aug 7, 2026
traded Aug 7, 2026
+0dSEC FORM 4

Evidence

5
HC
Hite ChristopherEVP & Chairman, Partnering
RPRXRoyalty Pharma plc
Grant or award
A—
11.0K sh
Aug 5, 2026Aug 7, 2026
traded Aug 5, 2026
+2dSEC FORM 4

Evidence

2
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Grant or award
A—
8,252 sh
Aug 5, 2026Aug 7, 2026
traded Aug 5, 2026
+2dSEC FORM 4

Evidence

2
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Grant or award
A—
11.0K sh
Aug 5, 2026Aug 7, 2026
traded Aug 5, 2026
+2dSEC FORM 4

Evidence

9
BL
Bassler Bonnie LDirector
RPRXRoyalty Pharma plc
Grant or award
A$37K
689 sh
Jun 30, 2026Jun 30, 2026
traded Jun 30, 2026
+0dSEC FORM 4

Evidence

23
HC
Hite ChristopherEVP & Chairman, Partnering
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$6.41M
117.6K sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC FORM 4

Evidence

17
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$502K
9,098 sh
Jun 24, 2026Jun 25, 2026
traded Jun 24, 2026
+1dSEC FORM 4

Evidence

19
HC
Hite ChristopherEVP & Chairman, Partnering
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$1.75M
32.4K sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC FORM 4

Evidence

1
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$93K
1,875 sh
Apr 28, 2026Apr 30, 2026
traded Apr 28, 2026
+2dSEC FORM 4

Evidence

19
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$1.64M
32.9K sh
Apr 28, 2026Apr 30, 2026
traded Apr 28, 2026
+2dSEC FORM 4

Evidence

1
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$85K
1,875 sh
Mar 23, 2026Mar 25, 2026
traded Mar 23, 2026
+2dSEC FORM 4

Evidence

15
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$1.50M
32.9K sh
Mar 23, 2026Mar 25, 2026
traded Mar 23, 2026
+2dSEC FORM 4

Evidence

14
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Grant or award
A—
20.0K sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC FORM 4

Evidence

14
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Grant or award
A—
26.6K sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC FORM 4

Evidence

9
HC
Hite ChristopherEVP & Vice Chairman
RPRXRoyalty Pharma plc
Grant or award
A—
26.6K sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC FORM 4

Evidence

21
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$805K
20.0K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

22
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$2.59M
65.8K sh
Jan 20, 2026Jan 23, 2026
traded Jan 20, 2026
+3dSEC FORM 4

Evidence

16
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$148K
3,750 sh
Jan 20, 2026Jan 23, 2026
traded Jan 20, 2026
+3dSEC FORM 4

Evidence

20
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$790K
20.0K sh
Jan 16, 2026Jan 20, 2026
traded Jan 16, 2026
+4dSEC FORM 4

Evidence

20
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$816K
20.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$786K
20.0K sh
Dec 26, 2025Dec 29, 2025
traded Dec 26, 2025
+3dSEC FORM 4

Evidence

16
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$768K
20.0K sh
Dec 19, 2025Dec 22, 2025
traded Dec 19, 2025
+3dSEC FORM 4

Evidence

24
LW
Lloyd George W.EVP, Investments & CLO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$3.06M
79.3K sh
Dec 17, 2025Dec 19, 2025
traded Dec 17, 2025
+2dSEC FORM 4

Evidence

24
LW
Lloyd George W.EVP, Investments & CLO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$1.18M
30.7K sh
Dec 18, 2025Dec 19, 2025
traded Dec 18, 2025
+1dSEC FORM 4

Evidence

25
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$914K
23.3K sh
Dec 5, 2025Dec 9, 2025
traded Dec 5, 2025
+4dSEC FORM 4

Evidence

33
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$714K
18.2K sh
Dec 5, 2025Dec 9, 2025
traded Dec 5, 2025
+4dSEC FORM 4

Evidence

29
LW
Lloyd George W.EVP, Investments & CLO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$4.38M
110.0K sh
Dec 3, 2025Dec 5, 2025
traded Dec 3, 2025
+2dSEC FORM 4

Evidence

11
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$24K
624 sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence

24
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$2.13M
55.1K sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence

17
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$406K
10.7K sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence

18
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$121K
3,126 sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence

31
LW
Lloyd George W.EVP, Investments & CLO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$1.83M
47.8K sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence

28
LW
Lloyd George W.EVP, Investments & CLO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$977K
25.5K sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence

25
LW
Lloyd George W.EVP, Investments & CLO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$179K
4,599 sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence

31
LW
Lloyd George W.EVP, Investments & CLO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$1.81M
47.4K sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence

21
LW
Lloyd George W.EVP, Investments & CLO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$181K
4,628 sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence

25
LW
Lloyd George W.EVP, Investments & CLO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$96K
2,470 sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence

25
LW
Lloyd George W.EVP, Investments & CLO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$106K
2,770 sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence

22
LW
Lloyd George W.EVP, Investments & CLO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$8,978
230 sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence

17
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$147K
3,750 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

23
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$2.59M
65.8K sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

21
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Derivative conversion
C—
160.0K sh
Nov 7, 2025Nov 7, 2025
traded Nov 7, 2025
+0dSEC FORM 4

Evidence

13
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Derivative conversion
C—
16.0K sh
Nov 7, 2025Nov 7, 2025
traded Nov 7, 2025
+0dSEC FORM 4

Evidence

13
LW
Lloyd George W.EVP, Investments & CLO
RPRXRoyalty Pharma plc
Grant or award
A—
6,168 sh
Nov 5, 2025Nov 7, 2025
traded Nov 5, 2025
+2dSEC FORM 4

Evidence

13
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Grant or award
A—
6,168 sh
Nov 5, 2025Nov 7, 2025
traded Nov 5, 2025
+2dSEC FORM 4

Evidence

9
HC
Hite ChristopherEVP & Vice Chairman
RPRXRoyalty Pharma plc
Grant or award
A—
6,168 sh
Nov 5, 2025Nov 7, 2025
traded Nov 5, 2025
+2dSEC FORM 4

Evidence

13
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Grant or award
A—
4,626 sh
Nov 5, 2025Nov 7, 2025
traded Nov 5, 2025
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Coyne Terrance P.EVP & CFO · Nov 7, 2025
  • ← Insider ofevidence
    Lloyd George W.EVP, Investments & CLO · Nov 7, 2025